{"id":795283,"date":"2026-03-11T19:40:02","date_gmt":"2026-03-11T19:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=795283"},"modified":"2026-03-11T19:40:02","modified_gmt":"2026-03-11T19:40:02","slug":"multiple-sclerosis-pipeline-expands-with-80-drugs-and-75-companies-advancing-nextgeneration-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-sclerosis-pipeline-expands-with-80-drugs-and-75-companies-advancing-nextgeneration-therapies-delveinsight_795283.html","title":{"rendered":"Multiple Sclerosis Pipeline Expands with 80+ Drugs and 75+ Companies Advancing Next-Generation Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773254370.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Multiple Sclerosis Pipeline Expands with 80+ Drugs and 75+ Companies Advancing Next-Generation Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773254370.jpg\" alt=\"Multiple Sclerosis Pipeline Expands with 80+ Drugs and 75+ Companies Advancing Next-Generation Therapies | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Multiple Sclerosis Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Multiple Sclerosis companies include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Multiple Sclerosis Pipeline Insight 2026&rdquo;<\/strong> report delivers detailed intelligence on more than <strong>75 organizations and over 80 investigational therapies<\/strong> within the multiple sclerosis development pipeline. The report evaluates drug profiles across both <strong>clinical and preclinical stages<\/strong>. It also assesses therapeutic candidates based on <strong>product category, development phase, route of administration, and molecular classification<\/strong>. Additionally, the study outlines <strong>discontinued or inactive pipeline assets<\/strong> in this therapeutic area.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore the newest therapies and emerging treatment opportunities within the Multiple Sclerosis pipeline. Access DelveInsight&rsquo;s comprehensive research report today! @ Multiple Sclerosis Pipeline Outlook @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the Multiple Sclerosis Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>January 20, 2026:<\/strong> The <strong>National Institute of Allergy and Infectious Diseases (NIAID)<\/strong> initiated a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the discontinuation of <strong>OCR therapy<\/strong> in individuals with early <strong>relapsing multiple sclerosis (RMS)<\/strong>. Eligible participants will begin OCR treatment following the approved dosing schedule&mdash;two <strong>300 mg infusions separated by 14 days<\/strong> (Day 0 and Day 14) totaling <strong>600 mg<\/strong>, followed by <strong>600 mg infusions at Months 6, 12, 18, and 24<\/strong>. At <strong>Month 24<\/strong>, patients will be randomized in a <strong>2:1 ratio<\/strong> into two groups beginning treatment at <strong>Month 30<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Arm 1:<\/strong> placebo infusion every six months<\/li>\n<li><strong>Arm 2:<\/strong> OCR infusion every six months<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The study&rsquo;s treatment duration will extend for <strong>48 months<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>January 16, 2026:<\/strong> <strong>Sanofi<\/strong> announced a clinical trial aimed at assessing the <strong>efficacy of frexalimab<\/strong> in delaying disability progression and evaluating safety during <strong>36 months of double-blind treatment<\/strong> compared with placebo. The trial includes <strong>male and female patients aged 18&ndash;60<\/strong> diagnosed with <strong>non-relapsing secondary progressive multiple sclerosis (nrSPMS)<\/strong> who meet the defined eligibility criteria.<\/p>\n<p style=\"text-align: justify;\"><strong>January 08, 2026:<\/strong> <strong>Hoffmann-La Roche<\/strong> launched a clinical study to examine the <strong>bioequivalence of a subcutaneous (SC) test formulation of ocrelizumab<\/strong> compared with the marketed reference formulation in patients with <strong>relapsing multiple sclerosis (RMS)<\/strong> or <strong>primary progressive multiple sclerosis (PPMS)<\/strong>. The study includes <strong>two phases<\/strong>:<\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Controlled phase:<\/strong> Participants receive either the test or reference formulation.<\/li>\n<li><strong>Continuation phase:<\/strong> All participants receive the <strong>test formulation of ocrelizumab SC<\/strong>.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">According to DelveInsight&rsquo;s analysis, the <strong>Multiple Sclerosis therapeutic pipeline<\/strong> remains highly active, with <strong>over 75 pharmaceutical and biotech companies<\/strong> advancing <strong>more than 80 innovative therapies<\/strong> aimed at improving treatment outcomes.<\/p>\n<p style=\"text-align: justify;\">Prominent companies involved in the <strong>Multiple Sclerosis drug development space<\/strong> include <strong>Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse<\/strong>, and others.<\/p>\n<p style=\"text-align: justify;\">Notable investigational and approved therapies shaping the pipeline include <strong>11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera<\/strong>, and several other candidates.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Stay updated with the latest developments in Multiple Sclerosis therapeutics. Gain insights into clinical studies, novel drugs, and key pharmaceutical players through DelveInsight&rsquo;s analysis @ Multiple Sclerosis Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Overview of the Multiple Sclerosis Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Multiple Sclerosis Pipeline Insight report<\/strong> offers a detailed review of the disease background, ongoing research activities, and therapeutic evaluation of key drug candidates currently under development. The report also identifies <strong>major unmet medical needs<\/strong> and areas where innovation is required to improve treatment options for patients with Multiple Sclerosis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Multiple Sclerosis: Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Multiple Sclerosis (MS) is one of the <strong>most prevalent neurological disorders affecting young adults<\/strong>, with initial symptoms commonly appearing between <strong>20 and 40 years of age<\/strong>. The disease targets the <strong>axons of the central nervous system<\/strong>, which are protected by <strong>myelin (white matter)<\/strong>. Damage to this protective layer disrupts nerve signaling and leads to a range of neurological symptoms.<\/p>\n<p style=\"text-align: justify;\">The most common form of the disease is <strong>Relapsing&ndash;Remitting Multiple Sclerosis (RRMS)<\/strong>, accounting for approximately <strong>85% of MS cases<\/strong>. RRMS is characterized by <strong>periodic relapses or flare-ups<\/strong>, followed by phases of <strong>remission<\/strong>, during which symptoms partially or completely subside.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Drug Profiles for Multiple Sclerosis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>IMU-838: Immunic Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Vidofludimus calcium (IMU-838)<\/strong> is an investigational small-molecule therapy being developed as an <strong>oral tablet<\/strong> for treating <strong>relapsing-remitting multiple sclerosis (RRMS)<\/strong>, <strong>inflammatory bowel disease<\/strong>, and other autoimmune disorders. Encouraging results from the <strong>Phase II EMPhASIS clinical trial<\/strong> indicate the drug may offer <strong>significant therapeutic advantages<\/strong>, particularly in early-stage RMS patients. The therapy demonstrates a <strong>placebo-like safety profile<\/strong> combined with <strong>strong anti-inflammatory and neuroprotective effects<\/strong>, supporting its potential as a promising treatment option.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>BIIB091: Biogen<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>BIIB091<\/strong> is designed to selectively inhibit <strong>Bruton&rsquo;s tyrosine kinase (BTK)<\/strong>, a non-receptor enzyme involved in regulating <strong>B-cell and myeloid cell signaling<\/strong>, both of which play roles in the pathogenesis of MS. BTK also influences <strong>Fc gamma receptor signaling<\/strong>, which activates myeloid immune cells. Preclinical studies show that <strong>BIIB091 exhibits high potency, favorable drug-like characteristics, and a promising safety profile<\/strong>, supporting its development as a <strong>reversible and selective BTK inhibitor<\/strong> for autoimmune diseases such as MS. The therapy is currently undergoing <strong>Phase II clinical evaluation<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>IMCY-0141: ImCyse<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>IMCY-0141<\/strong> represents the second clinical-stage candidate from <strong>ImCyse<\/strong>. This <strong>Imotope-based therapy<\/strong> is engineered from <strong>myelin oligodendrocyte glycoprotein (MOG)<\/strong> and is designed to <strong>halt MS progression<\/strong> by preventing the immune system from attacking the central nervous system. Preclinical studies have demonstrated <strong>promising immune responses<\/strong>, supporting its proposed mechanism of action and suggesting <strong>long-lasting therapeutic effects with less frequent dosing<\/strong>. Early intervention with this therapy may enable patients to experience <strong>minimal disease burden<\/strong>. The candidate is currently being studied in <strong>Phase I\/II clinical trials<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>CC-97540: Bristol-Myers Squibb<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CC-97540<\/strong> is an experimental therapy from <strong>Bristol-Myers Squibb<\/strong> developed as a <strong>selective oral inhibitor of tyrosine kinase 2 (TYK2)<\/strong>. TYK2 plays a critical role in the signaling pathways of <strong>pro-inflammatory cytokines<\/strong> such as <strong>IL-12, IL-23, and type I interferons<\/strong>, which are involved in autoimmune and inflammatory diseases. By specifically targeting TYK2 while avoiding significant inhibition of other <strong>JAK family enzymes<\/strong>, the drug may reduce inflammation with <strong>fewer adverse effects compared to broader JAK inhibitors<\/strong>. Although it is also being studied for conditions such as <strong>psoriasis and systemic lupus erythematosus<\/strong>, the therapy is currently in <strong>Phase I trials for Multiple Sclerosis<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore innovative therapeutic strategies and clinical research shaping the Multiple Sclerosis treatment landscape. Access DelveInsight&rsquo;s full report today! @ New Multiple Sclerosis Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Insights Offered in the Multiple Sclerosis Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides <strong>in-depth insights into pharmaceutical and biotechnology companies<\/strong> working on therapies for Multiple Sclerosis, along with the number of candidates developed by each organization.<\/p>\n<p style=\"text-align: justify;\">It categorizes therapeutic candidates across <strong>early-stage, mid-stage, and late-stage clinical development<\/strong>, offering a comprehensive view of ongoing research efforts.<\/p>\n<p style=\"text-align: justify;\">The report also identifies <strong>active, dormant, and discontinued drug development programs<\/strong>, providing a complete understanding of the pipeline dynamics.<\/p>\n<p style=\"text-align: justify;\">Additionally, the report evaluates pipeline drugs based on several parameters including:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Stage of development<\/strong><\/li>\n<li><strong>Route of administration<\/strong><\/li>\n<li><strong>Target receptor<\/strong><\/li>\n<li><strong>Monotherapy vs. combination therapy<\/strong><\/li>\n<li><strong>Mechanism of action<\/strong><\/li>\n<li><strong>Molecular type<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">It also includes <strong>detailed analysis of collaborations, licensing agreements, and funding activities<\/strong>, including <strong>company-to-company and academia partnerships<\/strong>, which support the advancement of new MS treatments.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Leading Companies in the Multiple Sclerosis Pipeline<\/strong><\/p>\n<p style=\"text-align: justify;\">Key players involved in developing Multiple Sclerosis treatments include <strong>Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse<\/strong>, among others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration Categories<\/strong><\/p>\n<p style=\"text-align: justify;\">Pipeline therapies for Multiple Sclerosis are being developed across several <strong>routes of administration<\/strong>, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Types Under Development<\/strong><\/p>\n<p style=\"text-align: justify;\">The report also categorizes MS pipeline drugs by <strong>molecular type<\/strong>, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecules<\/li>\n<li>Monoclonal antibodies<\/li>\n<li>Peptides<\/li>\n<li>Polymers<\/li>\n<li>Gene therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the future outlook for Multiple Sclerosis treatments. Learn about emerging drugs, innovative therapies, and leading industry participants through DelveInsight&rsquo;s expert analysis @ Multiple Sclerosis Market Drivers and Barriers &#8211; @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Multiple Sclerosis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:<\/strong> Global<\/li>\n<li><strong>Key Companies:<\/strong> Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.<\/li>\n<li><strong>Key Therapies:<\/strong> 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and additional candidates.<\/li>\n<li><strong>Therapeutic Assessment by Product Type:<\/strong> Monotherapy, Combination Therapy, Mono\/Combination<\/li>\n<li><strong>Clinical Development Stages Covered:<\/strong> Discovery, Preclinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Access the latest insights on Multiple Sclerosis therapies and ongoing clinical trials. Download DelveInsight&rsquo;s comprehensive pipeline analysis today! @ Multiple Sclerosis Companies, Key Products and Unmet Needs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a <strong>leading healthcare market research and consulting organization<\/strong> dedicated to delivering <strong>high-quality market intelligence and strategic insights<\/strong> that support informed business decisions. With a team of experienced analysts and deep expertise in the <strong>life sciences and healthcare sectors<\/strong>, the company provides <strong>customized research solutions and actionable insights<\/strong> to clients worldwide. Connect with DelveInsight to access <strong>accurate, timely, and strategic intelligence<\/strong> that helps organizations stay ahead in a rapidly evolving healthcare landscape.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=multiple-sclerosis-pipeline-expands-with-80-drugs-and-75-companies-advancing-nextgeneration-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=multiple-sclerosis-pipeline-expands-with-80-drugs-and-75-companies-advancing-nextgeneration-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Multiple Sclerosis Pipeline Multiple Sclerosis companies include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/multiple-sclerosis-pipeline-expands-with-80-drugs-and-75-companies-advancing-nextgeneration-therapies-delveinsight_795283.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-795283","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/795283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=795283"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/795283\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=795283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=795283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=795283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}